420. NCI Database Repository [Электронный ресурс]. – Режим доступа:
https://dtp.cancer.gov/organization/dscb/obtaining/default.htm.
421.
Negwer, M.H.
Organic-Chemical Drugs and Their Synonyms [Текст] /
M. Negwer, H.G. Scharnow. – 8th Edition. – Wiley-VCH. – 2001. – 4305 р.
422. Notice to Applicants. Volume 2A. Procedures for Marketing Authorisation.
Chapter 1 Marketing Authorisation [Электронный ресурс]. – Режим доступа:
ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/vol2a_chap1_en.pdf.
423.
Odum, J
. Technology Transfer as a Strategic Tool: Bridging the Valley of
Death [Текст] / J. Odum// Engineering. – 2007. – V. 27. – №5.
424. OECD Principles of good laboratory practice: Quality, Efficacy.
Guide 1:1998. [Электронный ресурс]. – Режим доступа: www.oecd.org/
chemicalsafety/testing/good-laboratory-practiceglp.htm.
425. OECD Principles for the validation, for regulatory purposes, of (quantita-
tive) structure-activity relationship models [Электронный ресурс]. – Режим до-
ступа: https://www.oecd.org/chemicalsafety/risk-assessment/37849783.pdf.
426.
Oprea, T.I
. Property distribution of drug-related chemical databases
[Текст] / T. I. Oprea // Journal of Computer-Aided Molecular Design. – 2000. –
V. 14, №3. – р. 251–264.
427. Optibrium [Электронный ресурс]. – Режим доступа: www.optibrium.
com/.
428. Orange Book: Approved Drug Products with Therapeutic Equivalence
Evaluations (39 ed.) [Электронный ресурс] / Food and Drug administration. –
2015. – Режим доступа: www.accessdata. fda.gov/scripts/Cder/ob/.
429.
Pagadala, N.S.
Software for molecular docking: a review [Текст] /
N.S. Pagadala, K. Syed, J. Tuszynski // Biophysical Reviews. – 2017. – V. 9,
№2. – р. 91–102.
430. Phases of clinical trials. NCCN [Электронный ресурс]. – Режим до-
ступа: www.nccn.org/patients/resources/clinical_trials/phases.aspx.
431.
Phillips, M.A
. Has molecular docking
ever brought us a medi-
cine? [Электронный ресурс]: In book: Molecular Docking / M. A. Phillips,
M.A. Stewart, D.L. Woodling [et al.]. – IntechOpen, 2018. – Режим доступа:
www.intechopen.com/books/molecular-docking/has-molecular-docking-ev-
er-brought-us-a-medicine.
432.
Pogodin, P.V
. AntiBac-Pred: A web portal for predicting antibacterial
activity of chemical compounds [Текст] / P.V. Pogodin, A.A. Lagunin, A. V.rudik
[et al.] // Journal of Chemical Information and Modeling. – 2019.
433.
Pogodin, P.V
. PASS Targets: ligand-based
multi-target computational
system based on public data and naïve Bayes approach [Текст] / P.V. Pogodin,
A.A. Lagunin, D.A. Filimonov [et al.] // SAR and QSAR in Environmental
Research. – 2015. –V. 26, №10. – р. 783–793.
434.
Polishchuk, P
. Structural and physico–chemical interpretation (SPCI) of
QSAR models and its comparison with matched molecular pair analysis [Текст] /
P. Polishchuk, O. Tinkov, T. Khristova [et al.] // Journal of Chemical Information
and Modeling. – 2016. – V. 56, №8. – р. 1455–1469.
435.
Poroikov, V
. 20th EuroQSAR: Understanding Chemical–Biological
Interactions / V. Poroikov // Molecular Informatics. – 2015. – V. 34, №6–7. –
р. 340.
Список литературы
387
436.
Poroikov, V
. PharmaExpert: diseases, targets and ligands – three in
one [Текст] / V. Poroikov, A. Lagunin, D. Filimonov // QSAR and Molecular
Modelling in Rational Design of Bioactive Molecules. – Ankara: CADD & D
Society, 2005. – p. 514–515.
437.
Poroikov, V.V
. Robustness of biological
activity spectra predicting
by computer program PASS for non-congeneric sets of chemical compounds /
V. V. Poroikov, D.A. Filimonov, Yu. V. Borodina [et al.] // Journal of Chemical
Information and Computer Sciences. – 2000. – V. 40, №6. – р. 1349–1355.
438. Proposal to waive in vivo bioequivalence requirements for the WHO
model list of essential medicines immediate release,
solid oral dosage forms
[Электронный ресурс]. – World Health Organization. – 2005. – Режим досту-
па: https://www.who.int/medicines/areas/quality_safety/quality_assurance/Prop
osalWaiveVivoBioequivalenceRequirementsModelListEssentialMedicinesImme
diateReleaseSolidOralDosageFormsTRS937.pdf.
439. ProteinDataBank [Электронный ресурс]. – Режим доступа: www.
rcsb.org/.
440. PubChem [Электронный ресурс]. – Режим доступа: pubchem. ncbi.
nlm.nih.gov/.
441.
Pucci, M.J
. Targets, targets everywhere – so where are the new
antibacterial drugs? / M.J. Pucci, T.J. Dougherty, J.F. Barrett// IDrugs. – 2000. –
V. 3, №3. – р. 249–250.
442. Quality Guidelines от International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human Use (ICH) [Электрон-
ный ресурс]. – Режим доступа: www.ich.org/products/guidelines/quality/
article/quality-guidelines.html.
443. Quality Risk Management / Implementation of ICH Q9 in the
pharmaceutical field an example of methodology from PIC/S [Текст]. – PS/
INF 1. – 2010. – 30 p.
444. Questions and Answers on Design Space Verification. ICH Quality IWG:
Points to Consider for ICH Q8/Q9/Q10 Implementation. EMA/603905/2013
[Электронный ресурс]. – Режим доступа: www.ema.europa.eu/en/documents/
other/questions-answers-design-space-verification_en.pdf.
445.
Ramsay, R
.
R
A perspective on multi–target drug discovery and design
for complex diseases [Текст] / R.R. Ramsay, M.R. Popovic-Nikolic, K. Nikolic
[et al.] // Clinical and Translational Medicine. – 2018. – V. 1, №7. – р. 3.
446.
Raju, T.N
. The Nobel chronicles. 1988: James Whyte Black, (b 1924),
Gertrude Elion (1918–99), and George H Hitchings (1905–98) [Текст] /
T.N. Raju // Lancet. – 2000. – V. 355. – p. 1022.
447.
Ruddigkeit, L
. Visualization and virtual
screening of the chemical
universe database GDB-17 [Текст] / L.ruddigkeit, L.C. Blum, J.L. Reymond
// Journal of Chemical Information and Modeling. – 2013. – V. 1, №53. – р.
56–65.
448.
Rusinov, V.L.
Synthesis and Evaluation of Novel [1, 2, 4]Triazolo [5, 1-c]
[1, 2, 4]–triazines and Pyrazolo [5, 1-c] [1, 2, 4] triazines as Potential Antidiabetic
Agents [Электронный ресурс] / V.L. Rusinov, I.M. Sapozhnikova, A.M. Bliznik
[et al.] // Archiv der Pharmazie – 2017. – V. 350, №5. – Режим доступа: https://
www.ncbi.nlm.nih.gov/pubmed/28393419.
388
Достарыңызбен бөлісу: